Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease.

Publication Type:

Journal Article

Source:

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 28, Issue 23, p.3701-8 (2010)

Keywords:

2010, Adult, Aged, Antibodies, Monoclonal, Center-Authored Paper, Female, Giant Lymph Node Hyperplasia, Humans, Interleukin-6, Male, Middle Aged, Vaccine and Infectious Disease Division, Young Adult

Abstract:

Interleukin-6 (IL-6) has emerged as a key factor in the pathogenesis of the atypical lymphoproliferative disorder Castleman's disease (CD). Siltuximab is a new anti-IL-6, chimeric monoclonal antibody with potential therapeutic benefit in patients with CD.